Dyne Therapeutics (NASDAQ:DYN) Price Target Cut to $17.00 by Analysts at JPMorgan Chase & Co.

Dyne Therapeutics (NASDAQ:DYN) had its price objective reduced by stock analysts at JPMorgan Chase & Co. from $18.00 to $17.00 in a report issued on Friday,Benzinga reports. The brokerage presently has a “neutral” rating on the stock. JPMorgan Chase & Co.‘s price objective would indicate a potential downside of 10.43% from the stock’s previous close.

DYN has been the subject of several other reports. HC Wainwright upped their target price on shares of Dyne Therapeutics from $38.00 to $46.00 and gave the company a “buy” rating in a research note on Thursday, November 6th. Oppenheimer cut their price objective on shares of Dyne Therapeutics from $13.00 to $11.00 and set a “market perform” rating for the company in a research report on Wednesday. Chardan Capital lowered their price target on Dyne Therapeutics from $50.00 to $38.00 and set a “buy” rating on the stock in a research note on Tuesday, July 29th. Royal Bank Of Canada raised their price objective on Dyne Therapeutics from $23.00 to $30.00 and gave the stock an “outperform” rating in a research note on Thursday, November 6th. Finally, Lifesci Capital raised shares of Dyne Therapeutics to a “strong-buy” rating in a report on Tuesday, October 14th. Four analysts have rated the stock with a Strong Buy rating, ten have issued a Buy rating, three have assigned a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average target price of $34.93.

Dyne Therapeutics Stock Performance

Dyne Therapeutics stock traded up $0.15 during mid-day trading on Friday, hitting $18.98. 1,142,652 shares of the company’s stock traded hands, compared to its average volume of 2,634,699. The company has a quick ratio of 16.83, a current ratio of 16.83 and a debt-to-equity ratio of 0.17. Dyne Therapeutics has a one year low of $6.36 and a one year high of $31.32. The firm has a 50 day moving average price of $16.09 and a 200 day moving average price of $12.98. The company has a market cap of $2.71 billion, a PE ratio of -4.92 and a beta of 1.16.

Dyne Therapeutics (NASDAQ:DYN) last issued its quarterly earnings data on Wednesday, November 5th. The company reported ($0.76) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.81) by $0.05. On average, equities analysts forecast that Dyne Therapeutics will post -3.44 EPS for the current year.

Insider Activity

In related news, CEO John Cox sold 2,640 shares of the business’s stock in a transaction on Friday, September 5th. The shares were sold at an average price of $13.41, for a total transaction of $35,402.40. Following the transaction, the chief executive officer owned 199,539 shares in the company, valued at $2,675,817.99. The trade was a 1.31% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. 14.14% of the stock is owned by corporate insiders.

Hedge Funds Weigh In On Dyne Therapeutics

A number of hedge funds and other institutional investors have recently modified their holdings of DYN. CWM LLC lifted its holdings in Dyne Therapeutics by 168.1% during the second quarter. CWM LLC now owns 3,030 shares of the company’s stock worth $29,000 after acquiring an additional 1,900 shares during the period. Chung Wu Investment Group LLC bought a new position in shares of Dyne Therapeutics in the third quarter valued at approximately $30,000. Caitong International Asset Management Co. Ltd grew its stake in Dyne Therapeutics by 378.6% during the first quarter. Caitong International Asset Management Co. Ltd now owns 3,092 shares of the company’s stock valued at $32,000 after acquiring an additional 2,446 shares in the last quarter. Quarry LP purchased a new stake in Dyne Therapeutics in the 1st quarter worth approximately $47,000. Finally, Mirae Asset Global Investments Co. Ltd. lifted its holdings in shares of Dyne Therapeutics by 25.3% in the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 5,500 shares of the company’s stock worth $70,000 after acquiring an additional 1,109 shares during the last quarter. Hedge funds and other institutional investors own 96.68% of the company’s stock.

Dyne Therapeutics Company Profile

Dyne Therapeutics, Inc, a clinical-stage muscle disease company, operates as a biotechnology company that focuses on advancing therapeutics for genetically driven muscle diseases in the United States. It is developing a portfolio of muscle disease therapeutics, including programs in myotonic dystrophy type 1; duchenne muscular dystrophy; and facioscapulohumeral dystrophy, as well as rare skeletal muscle, and cardiac and metabolic muscle diseases using its FORCE platform that delivers disease-modifying therapeutics.